EV7404053588 US

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE UNFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APR 2 8 2004

TRADEMAR

Sheet 1 of 4

ATTORNEY DOCKET NO.	SERIAL NO.	
1748-000001/US	10/766,22	26
APPLICANT	L	
Benjamin A. Buscher, et. al		
FILING DATE	GROUP	<u>: : :</u>
January 28, 2004	unknown	

U.S. P	ATENT DO	CUMENTS				
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate)
1.	MFS	4,865,967	Sep 12, 1989	Shiraishi et al.	435/6	Filing Date Nov. 30, 1987
2.		4,980,281	Dec. 25, 1990	Housey	435/29	Feb. 10, 1988
3.		5,118,601	Jun. 2, 1992	Gruber	435/5	Aug. 31, 1989
4.		5,266,464	Nov. 30, 1993	Housey	435/29	Aug. 10, 1989
5.		5,358,721	Oct. 25, 1994	Guittard et al.	424/473	Dec. 4, 1992
6.		5,366,862	Nov. 22, 1994	Venton et al.	435/7.1	
7.		5,384,243	Jan. 24, 1995	Gutkind et al.	435/6	Aug. 21, 1992
8.		5,510,240	Apr. 23, 1996	Lam et al.	435/7.1	Dec. 11, 1992
9.		5,547,841	Aug. 20, 1996	Marotta et al.	 	Feb. 8, 1993
10.		5,591,646	Jan. 7, 1997	Hudson et al.	435/6	Dec. 15, 1992
11.		5,601,975	Feb. 11, 1997	Bonyhadi et al.	436/518	Sep. 2, 1992
12.		5,645,982	Jul. 8, 1997		435/5	Jun. 6, 1995
13.		5,688,655		Bonyhadi et al.	435/5	Aug. 19, 1993
14.		——————————————————————————————————————	Nov. 18, 1997	Housey	435/7.21	Mar. 17, 1995
		5,738,985	Apr. 14, 1998	Miles et al.	435/5	Apr. 1, 1994
15.		5,747,338	May 5, 1998	Giese et al.	435/348	Sep. 25, 1996
16.		5,814,460	Sep. 29, 1998	Venton et al.	435/7.1	Aug. 9, 1993
17.		5,830,644	Nov. 3, 1998	West et al.	435/6	Nov. 12, 1993
18.		5,843,693	Dec. 1, 1998	Halenbeck et al.	435/23	Feb. 27, 1995
19.		5,872,015	Feb. 16, 1999	Venton et al.	436/538	May 10, 1996
20.		5,877,007	Mar. 2, 1999	Housey	435/252.3	Jun. 7, 1995
21.	AFS	6,107,059	Aug. 22, 2000	Hart	435/69.7	Apr. 29, 1992

Evaminary 0 4 4 4		1	
Examiner: W. Jaan Val	Date Considered: /c /2 7 //5		
	10 7 10	<u> </u>	1

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 4

ATTORNEY DOCKET NO.	
	SERIAL NO.
1748-000001/US	10/766,226
APPLICANT	
Benjamin A. Buscher,	et al.
FILING DATE	GROUP
January 28, 2004	Unknown

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate)
22.	MRS	6,156,496	Dec. 5, 2000	Miles et al.	435/5	Filing Date Sep. 8, 1997
23.		US 6,172,047 B1	Jan. 9, 2001	Roizman et al.	514/44	Jun. 7, 1995
24.		US 6,207,861 B1	Mar. 27, 2001	Nash et al.	564/133	Feb. 17, 1998
25.		US 6,290,959 B1	Sep. 18, 2001	Wu et al.	424/150.1	Oct. 24, 1997
26.		US 6,319,668 B1	Nov. 20, 2001	Nova et al.	435/6	Jun. 24, 1996
27.		US 6,376,192 B1	Apr. 23, 2002	Elledge et al.	435/6	Nov. 28, 2000
28.		US 6,472,151 B1	Oct. 29, 2002	Weaver et al.	435/6	Aug. 10, 1999
29.		US 6,548,657 B1	Apr. 15, 2003	Burgin et al.	536/24.5	Dec. 18, 1998
30.		US 6,579,674 B2	Jun. 17, 2003	Miles et al.	435/5	Mar. 28, 2002
31.		US 2003/0138432 A1	Jul. 24, 2003	Glazier	424/178.1	Dec. 15, 2000
32.		US 2003/0152912 A1	Aug. 14, 2003	Dyall et al.	435/5	Jan. 29, 2002
33.		US 2003/0170613 A1	Sep. 11, 2003	Straus	435/5	Sep. 6, 2002
34.		US 6,623,961 B2	Sep. 23, 2003	Miles et al.	435/370	Mar. 28, 2002
35.		US 6,627,452 B1	Sep. 30, 2003	Volchek	436/150	Apr. 20, 2000
36.	mFS	US 2003/0198949 A1	Oct. 23, 2003	Goldmakher et al.	435/5	Jun. 18, 2003

FORE	IGN PATEN	IT DOCUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	ı No

Cupmina	a	~	1			_ :	
Examiner:	M	Ne	la	Date Considered: 10/27/	105		1
			1		0		;

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 4

ATTORNEY DOCKET No.	SERIAL NO.
1748-000001/US	10/766,226
APPLICANT	
Benjamin A. Buscher,	et al.
FILING DATE	GROUP
January 28, 2004	Unknown

Ref. Desig.	Examiner's Initials	
1.	mP) i	Shane Crotty, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen, Nature Medicine, Vol. 6, No. 12, December 2000 < http://medicine.nature.com>
2.		Michael Powers, et al., Development of a Real-Time Reverse Transcription PCR Multiplex Assay to Screen for Eastern, Western and Venezuelan Equine Encephalitis (C-318) presented May 21, 2003 at American Society of Microbiology General Meeting 2003 http://www.idahotech.com/contact_it/ASM/asm2003.htm
3.	\	DL Beck, et al. Disruption of Virus Movement Confers Broad-Spectrum Resistance Against Systemic Infection by Plant Viruses with a Triple Gene Block, National Academy of Science USA, October 25, 1994 http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstract&artid=45009
4.	\	W. Markland, et al. Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon, American Society for Microbiology, Antimicrob Agents Chemother, April 2000, http://www.pubmedcentral.gob/articlerender.fcgi?tool=pmcentrez&artid=89783
5.	1	New Broad Spectrum Anti-Viral-VX-497, Sept. 25, 1999, http://archive.mail-list.com/hbv_research/msg00270.html
6.	\	Ulrich Melcher, Molecular Genetics - Reporter genes, Oct. 7, 1997 http://opbs.okstate.edu/~melcher/MB/MGW4/MG429.html
7.	l V	Apath, LLC I Technology Available for Licensing, March 17, 2003 http://www.apath.com/Directory/Licensing/Licensing.asp
8.	\	National Center for Biotechnology Information - Taxonomy browser - ssRNA positive- strand viruses, no DNA stage, September 23, 2002 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi
9.		National Center for Biotechnology Information - Taxonomy browser - dsDNA viruses, no RNA stage, from Retroviruses, by Ed. J. M. Coffin et al, cold spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi
10.	nrs.	National Center for Biotechnology Information - Genome - Retroviruses, September 23, 2002 http://www.ncbi.nlm.nih.gov/retroviruses/genomes/genom.html

Examiner: W	We	la -	Date Considered:	10/27	Icr	:	
	$\overline{}$				/		

EXAMINER: Please initial of citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 4 of 4

ATTORNEY DOCKET NO.	SERIAL NO.
1748-000001/US	10/766,226
APPLICANT	
Benjamin A. Buscher,	et al.
FILING DATE	GROUP
January 28, 2004	Unknown

OTHE	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
Ref. Desig.	Examiner's Initials								
11.	MFS	Virus Taxonomy – 2002 in genomic order, June 28, 2002 < http://life.bio2.edu/lctv/fr-fst-g.htm							
12.	1	Apath, LLC I Screening Platform, March 17, 2003, http://www.apath.com/Directory/Screening_Platform/Screening_Platform.asp >							
13.		Vertex Pharma, Vertex Reports Six-Month Results from Phase II Clinical Study of Merimepodib (VX-497) in HCV, October 17, 2003 http://www.natap.org/2003/oct/101703_1.htm							
14.	\	Apath, LLC I Drug Discovery, Apath Antiviral Drug Discovery, March 17, 2003 http://www.apath.com/Directory/Antiviral_Drug_Discovery/Drug_Discovery.asp >							
15.	MES	Vertex Pharmaceuticals to Develop and Commercialize New Treatment for Hepatitis C Virus (HCV) Infection November 10, 2003 " http:="" stories.pl?acct="104&ST0RY=/www/story/11-10-2003/002055037&EDATE=" www.prnewswire.com="">"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www/story/11-10-2003/002055037&EDATE=>"http://www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www.prnewswire.com/cgibin/stories.pl?ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.com/cgibin/stories.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.com/cgibin/stories.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnewswire.pdf.ACCT=104&ST0RY=/www.prnews							

Examiner: M.	Mar	fo	1	Date Considered: 16/21/08	
	7	7			

EXAMINER: Please Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.